BioMotiv

Accelerating breakthrough discoveries into medicines, affiliated with The #HarringtonProject. #impinv #drugdevelopment #biotech #CLE

[Michelle Jarboe @mjarboe]

Tuned in to a virtual discussion this afternoon with Commerce Secretary Wilbur Ross, who praised the resilience of #CLE-area businesses but sounded the alarm on the city’s poor response rate to the census. ⁦@GCPartnership⁩ https://t.co/F1Qk5JadYp

[BioMotiv @BioMotiv]

Congratulations to Leen Adjalouni for making the Crain's 2020 Twenty in their 20s list #CRAINS20CLE #clevelandtalent

[Crain's Cleveland Business @CrainsCleveland]

Introducing Crain’s 2020 Twenty in their 20s -- Here you’ll find the typical roll call of accomplishments beyond their years, impressive feats of leadership, advocates, healers and entrepreneurs | Read more: https://t.co/DjM3xhSX98 #CRAINS20CLE

[BioMotiv @BioMotiv]

Great read - Cleveland can and must do better

[Crain's Cleveland Business @CrainsCleveland]

Letter from the publisher, @McIntyreCrains: Yes, we can — and must — do better on diversity https://t.co/uc4bBtgnHw

[BioMotiv @BioMotiv]

Congratulations to the Amphista Therapeutics team on their recent appointment of Dr. Ian Churcher, an internationally recognized leader in the field of targeted protein degradation, as Chief Scientific Officer. Read more here: https://t.co/GhHW9VI0S8
#CSO #cancertherapeutics

[Greater Cleveland Partnership @GreaterCLE]

We are seeing more retooling in our manufacturing sector to combat COVID-19.

Thank you, U.S. Cotton

#InThisTogetherCLE #ChamberStrong

#Cleveland company approved to make swabs for coronavirus testing https://t.co/txcCpDrV2B

[BioMotiv @BioMotiv]

Congrats to @athersys on their public offering of $57M! Proud to be a part of the #CLE #Biotech community @CrainsCleveland https://t.co/m0Bw6gqKB8

[BioMotiv @BioMotiv]

Exciting news from Cleveland-based SecondBreath on their FDA approval to produce ventilators for coronavirus patients. Inspiring to see CLE-based companies innovate and step-up during this crisis. https://t.co/LZiW6GTga4 #Cleveland #COVID19 #CLEresponds

[Athersys Inc @athersys]

FDA authorizes #Athersys to initiate a pivotal clinical trial evaluating #MultiStem Cell Therapy in patients with #COVID19 induced #ARDS. https://t.co/rvJLtLscK5

[BioMotiv @BioMotiv]

Excited to announce our investment in @AmphistaTherapeutics alongside Advent Life Sciences. Amphista Therapeutics is a biopharmaceutical company with a novel targeted protein degradation platform. Read more here: https://t.co/chCwzCphtO

[BioMotiv @BioMotiv]

We are excited to announce The Harrington Discovery Institute at @UHhospitals launched a five-part initiative to accelerate near-term therapies for treating Coronavirus and future pandemic threats. Learn more here: https://t.co/1h0CYsURA5

[Athersys Inc @athersys]

#Athersys CEO Gil Van Bokkelen was on @FoxNews on @AmericasNewsroom sharing the Athersys story about our #COVID19 induced #ARDS program using #MultiStem cell therapy. $ATHX https://t.co/4omNO9OQy2

[Baiju R. Shah @Baiju_R_Shah]

Advising a #COVID19 research initiative for #socialimpact.
Your #COVID19 experience as a patient or caregiver can make a difference. Join the Study Covid Project (https://t.co/9GZpXE59As) to help leaders make smarter decisions. @fastercures @metrohealthCLE @diabetesdaily

[BioMotiv @BioMotiv]

@MilkenInstitute has created a #COVID19 Treatment and Vaccine Tracker. Find the tracker here to get the latest on the development of 79 potential treatments and 49 vaccines: https://t.co/CEmu5egWHz

[University Hospitals @UHhospitals]

A COVID-19 (coronavirus) vaccine is in development - but what’s the process and when will it be available? Dr. Robert Salata, Program Director, UH Roe Green Center for Travel Medicine & Global Health, explains. #COVID19 #coronavirus

[Cleveland Foundation @CleveFoundation]

Help #CLE’s most vulnerable by contributing to the Greater #Cleveland #COVID19 Rapid Response Fund today: https://t.co/KBisZl3HPp. #CLEresponds #COVID19OhioReady

[BioMotiv @BioMotiv]

#KoutifTherapeutics, one of our portfolio companies, received $250,000 in grant funding from the Crohn's & Colitis Foundation to support the development of novel small molecule therapeutics for the treatment of #IBD and #Crohnsdisease. Read more here: https://t.co/msFj8azRc0

[BioMotiv @BioMotiv]

BioMotiv, associated with #TheHarringtonProject, and Bristol-Myers Squibb launch their first #biotech after the announcement of their partnership, Anteros Pharmaceuticals, focused on developing new class of drugs for #fibrotic and #inflammatorydiseases. https://t.co/BTz43DZVQa

[BioMotiv @BioMotiv]

One of our portfolio companies, Aro Biotherapeutics recently announced a licensing and collaboration agreement with a top tier pharmaceutical company, Ionis Pharmaceuticals – the leader in RNA based therapeutics. Read more here: https://t.co/saVR0w4FOx

[BioMotiv @BioMotiv]

BioMotiv and Atomwise announced a strategic collaboration today to integrate AI technology, drug development expertise and an ecosystem of partners for the commercialization of promising early-stage research: https://t.co/63xzSdwubX

[BioMotiv @BioMotiv]

There are approximately 100,000 patients with #retinitispigmentosa living in the US, but there is no cure for the disease. #OptiKira is developing compounds that would slow progression of the disease: https://t.co/BYVGcSBuHB

@fightblindness @arixbioscience @CRiverLabs